Hydrogel filament vaso-occlusive device

• US 20020193813A1
• Filed: 05/06/2002
• Published: 12/19/2002
• Est. Priority Date: 05/04/2001
• Status: Abandoned Application

• Current Assignee: Stryker Corporation
• Original Assignee: Concentric Medical, Inc. (Stryker Corporation)
• Inventors: Ken, Christopher G.M., Patel, Tina J., Helkowski, Richard A.
• Application Number:
  US10/138,535
• Publication Number:
  US 20020193813A1
• Time in Patent Office: Days
• US Class Current: 606/151
• CPC Class Codes: A61B 17/12022 Occluding by internal devices, e.g. balloons or releasable wires plugging an opening in the wall of an organ A61B17/0057; occluders for the cervical canal A61F6/146; vas deferens occluders A61F6/20
• CPC Class Codes: A61B 17/12113 within an aneurysm
• CPC Class Codes: A61B 17/1214 Coils or wires
• CPC Class Codes: A61B 17/12168 having a mesh structure A61B17/1214 takes precedence
• CPC Class Codes: A61B 17/1219 expandable in contact with liquids
• CPC Class Codes: A61L 24/0031 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 24/04 containing macromolecular materials
• CPC Class Codes: A61L 24/104 Gelatin
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices artificial blood vessels A61L27/507
• CPC Class Codes: A61L 31/04 Macromolecular materials
• CPC Class Codes: A61L 31/145 Hydrogels or hydrocolloids

Abstract

Methods and an apparatus for treating abnormal blood flow. The apparatus comprises a vaso-occlusive device of a hydratable filament comprising extruded polyacrylonitrile for implantation in a patient at a site of abnormal blood flow. The device treats ruptured blood vessels, aneurysms, arterio venus malformations (AVMs), fistulas and benign and malignant tumors. The methods include a method of making the vaso-occlusive device and methods of treating patients having abnormal blood flow by implanting the device at a site of abnormal blood flow.

Claims

1. A vaso-occlusive device for implantation into the vasculature of a patient to occlude blood flow comprising:

a hydratable filament comprising extruded polyacrylonitrile.

2. A vaso-occlusive device as in claim 1, further comprising a bioactive agent incorporated into the filament during extrusion or subsequent hydration of the filament resulting from extrusion;

wherein said bioactive agent acts in the patient to provide a biological activity at a site of implantation of the vaso-occlusive device.

3. A vaso-occlusive device as in claim 2, wherein the bioactive agent promotes an activity at the site of implantation selected from the group consisting of occludes blood flow, adheres the device at the site, rebuilds a damaged vascular wall, regresses or inhibits capillary dilation, regresses or inhibits venus malformation, and regresses or inhibits tumor growth at or near the implantation site.

4. A vaso-occlusive device as in claim 2, wherein the bioactive agent is selected from the group consisting of a protein factor, a growth factor, an inhibiting factor, an endothelization factor, an extracellular matrix-forming factor, a cell adhesion factor, a tissue adhesion factor, an immunological factor, a healing factor, a vascular endothelial growth factor, a scarring factor, a tumor suppressor, an antigen-binding factor, an anti-cancer factor, a monoclonal antibody, a monoclonal antibody against a growth factor, a drug, a drug producing cell, a cell regeneration factor, a progenitor cell of the same type as vascular tissue, and an a progenitor cell that is histiologically different from vascular tissue.

5. A vaso-occlusive device as in claim 1, further comprising a radio pacifier.

6. A vaso-occlusive device as in claim 5, wherein the radio pacifier comprises a contrast agent or a metal powder.

18. A vaso-occlusive device as in claim 2, wherein the bioactive agent is PGLA.

7. A method of making a vaso-occlusive device comprising a step of extruding a hydratable filament comprising polyacrylonitrile.

8. A method as in claim 7, further comprising steps of:

dissolving polyacrylonitrile in DMSO, extruding the DMSO solution into isopropyl alcohol, and forming a filament in the alcohol.

9. A method as in claim 8, further comprising evaporating the alcohol or removing the filament from the alcohol to dry.

10. A method as in claim 9, further comprising hydrating the dehydrated filament for storage or delivery into a patient.

11. A method of making a vaso-occlusive device as in claim 7, further comprising a step of integrating a bioactive agent into the extruded product.

12. A method of making a vaso-occlusive device as in claim 11, wherein integrating the bioactive agent into the extruded product is accomplished either during extrusion or after extrusion.

13. A method as in claim 12, wherein integrating the bioactive agent is accomplished after extrusion, and the post-extrusion integrating is selected from the acts consisting of coating, dipping, jacketing, spraying, weaving, braiding, spinning, ion implantation, vapor deposition and plasma deposition.

14. A method as in claim 12, wherein integrating the bioactive agent is accomplished during extrusion, and the integrating is accomplished by placing the bioactive agent into a solvent used to dissolve the polyacrylonitrile.

16. A method of treating a patient as in claim 15, further comprising coating the filament with a bioactive agent, or integrating a bioactive agent into the filament.

17. A method as in claim 15, wherein coating or integrating comprises a process selected from the group consisting of coating, dipping, jacketing, spraying, weaving, braiding, spinning, ion implantation, vapor deposition and plasma deposition.

19. A vaso-occlusive device as in claim 18, wherein the PGLA is formed by mixing PGA:

PLA in ratios ranging from about 99.9;

0.1 to about 50;

50.

20. A method as in claim 7, further comprising dissolving polyacrylonitrile in sodium thiocyanate, extruding the sodium thiocyanate into isopropyl alcohol, and forming a filament in the alcohol.

21. A method as in claim 20, further comprising evaporating the alcohol or removing the filament from the alcohol to dry.

22. A method as in claim 21, further comprising hydrating the dehydrated filament for storage or delivery into a patient.

15. A method of treating a patient having abnormal blood flow at a site in the patient comprising a step of:

injecting into the patient at the site of abnormal blood flow a material comprising an extruded hydrated filament comprising polyacrylonitrile.